In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales

被引:2
|
作者
Ozyurt, Ozlem K. [1 ]
Tufanoglu, Pinar [1 ]
Cetinkaya, Ozgul [2 ]
Ozhak, Betil [1 ]
Yazisiz, Hatice [1 ]
Ongut, Gozde [1 ]
Turhan, Ozge [3 ]
Ogunc, Dilara [1 ]
机构
[1] Akdeniz Univ, Fac Med, Dept Med Microbiol, Antalya, Turkey
[2] Univ Hlth Sci, Antalya Training & Res Hosp, Dept Med Microbiol, Antalya, Turkey
[3] Akdeniz Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Antalya, Turkey
关键词
RESISTANCE; COLISTIN;
D O I
10.7754/Clin.Lab.2022.220827
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Carbapenemase production is an issue of significant clinical and public health concern, because of the shortage of effective antimicrobial agents available for treatment. Here, we present antimicrobial susceptibili-ty data of ceftazidime-avibactam, cefiderocol, and other clinically relevant antibiotics for carbapenemase-produc-ing Enterobacterales bloodstream isolates, in accordance with European Committee on Antimicrobial Susceptibili-ty Testing (EUCAST) guidelines. Methods: A total of 133 carbapenemase producing Enterobacterales bloodstream isolates from May 2010 to Sep-tember 2018 were included in the study. Species were identified using matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (Bruker Daltonics, Germany). The presence of the blaKPC, blaNDM, blaOXA-48, blaVIM, and blaIMP carbapenemase genes were investigated by BD Max CRE assay (Becton Dickinson, USA) and in-house PCR. Antimicrobial susceptibility testing was performed by the BD Phoenix automated system (Becton Dickinson, USA), except cefiderocol and colistin. Cefiderocol and colistin susceptibility was determined by disk diffusion and broth microdilution method, respectively. Results: Except for cefiderocol and ceftazidime-avibactam, the percentage of susceptible isolates did not exceed 90% for any of the antibiotics tested. Although none of the isolates were resistant to cefiderocol, the ceftazidime-avibactam resistance rate was 9.8%. All of the ceftazidime-avibactam resistant strains were NDM (New Delhi metallo-beta-lactamases) producers. Among the other clinically relevant antibiotics tested, only amikacin, colistin, tigecycline, and fosfomycin susceptibility rates exceeded 50%. Of the 133 isolates 22.6% were resistant to colistin which is the preferred antibiotic with a second active agent for infections caused by metallo-beta-lactamase pro-ducing Enterobacterales in Turkey. Conclusions: In our study, resistance to ceftazidime-avibactam was detected only in metallo-beta-lactamase pro-ducing Enterobacterales isolates, while cefiderocol was found to be effective against all strains. It is important to monitor regional antimicrobial susceptibility data, as the emergence of antimicrobial resistant phenotypes is di-rectly linked to the use of any given antimicrobial agent.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 50 条
  • [1] In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales
    Romina, Papa-Ezdra
    Lucia, Araujo
    Leticia, Caiata
    Federica, Ferreira
    Pablo, Avila
    Veronica, Seija
    Antonio, Galiana
    Ines, Bado
    Rafael, Vignoli
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 35 : 62 - 66
  • [2] Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales
    Dietl, Beatriz
    Martinez, Laura M.
    Calbo, Esther
    Garau, Javier
    FUTURE MICROBIOLOGY, 2020, 15 (07) : 473 - 484
  • [3] In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae
    Zhang, Wenxia
    Guo, Yan
    Li, Jiayin
    Zhang, Yiyuan
    Yang, Yang
    Dong, Dong
    Zhu, Demei
    He, Ping
    Hu, Fupin
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2018, 7
  • [4] Ceftazidime-Avibactam Treatment for Carbapenemase-Producing Enterobacterales in a South African Children's Hospital
    Tootla, Hafsah Deepa
    Van Niekerk, Saamiya
    Gumede, Thandolwethu
    Nuttall, James
    Salie, Shamiel
    Eley, Brian
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2024,
  • [5] Assessment of in vitro activity of ceftazidime/avibactam on carbapenemase-producing Enterobacterales from Iran: An experimental study
    Haeili, Mehri
    Bavil-Olyaei, Parisa Ghaderi
    HEALTH SCIENCE REPORTS, 2024, 7 (08)
  • [6] Treating carbapenemase-producing Enterobacterales urosepsis with ceftazidime/avibactam in pregnancy
    Broderick, Claire
    Lebedevs, Tamara
    Hazelton, Briony
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 62 (03)
  • [7] TREATING CARBAPENEMASE-PRODUCING ENTEROBACTERALES UROSEPSIS WITH CEFTAZIDIME/AVIBACTAM IN PREGNANCY
    Kendrick, C.
    Lebedevs, T.
    Hazelton, B.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 31 : S45 - S45
  • [8] In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae
    Wenxia Zhang
    Yan Guo
    Jiayin Li
    Yiyuan Zhang
    Yang Yang
    Dong Dong
    Demei Zhu
    Ping He
    Fupin Hu
    Antimicrobial Resistance & Infection Control, 7
  • [9] Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
    Nordmann, Patrice
    Bouvier, Maxime
    Poirel, Laurent
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (09) : 1145 - 1152
  • [10] Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
    Patrice Nordmann
    Maxime Bouvier
    Laurent Poirel
    European Journal of Clinical Microbiology & Infectious Diseases, 2023, 42 : 1145 - 1152